Amgen Neuro Exec Marek Joins Axsome as Chief Commercial Officer

Axsome Therapeutics (NASDAQ: [[ticker:AXSM]]) has appointed David Marek to serve as chief commercial officer. Marek joins the New York biotech from Amgen (NASDAQ: [[ticker:AMGN]]), where he was vice president and general manager of the company’s neuroscience business unit. His experience also includes executive roles at WebMD and Saatchi & Saatchi Healthcare Advertising. Axsome is developing treatments for central nervous system disorders. The company’s pipeline includes late-stage programs in depression, agitation in Alzheimer’s disease, and migraine.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan